α放射性物質市場規模、佔有率和成長分析：按放射性核種、腫瘤內科領域、製造技術、醫療領域終端用戶和地區分類－2026-2033年產業預測

2024 年全球 α 射線發射材料市場價值為 12.5 億美元，預計到 2025 年將成長至 14.5 億美元，到 2033 年將成長至 46.8 億美元，在預測期（2026-2033 年）內複合年成長率為 15.8%。

隨著醫療專業人員尋求與傳統放射療法相比副作用最小的治療方法，全球α放射性物質市場正經歷顯著成長，這主要得益於精準腫瘤學需求的不斷成長。諸如225Ac-PSMA-617等創新產品的推出，促使製藥公司大力投資同位素生產和標記技術。醫院正在探索將α放射性物質與免疫療法合併使用，以增強腫瘤特異性免疫反應。此外，航太領域也正在探索鈽-238等替代同位素，進而拓展市場應用。人工智慧驅動的自動化正在重塑價值鏈，改善同位素發現、生產品質和臨床工作流程，進而提高治療的效率、可負擔性和安全性。多元化的應用和技術進步的整合正在推動α放射性物質市場的發展，並帶來創業投資投資的增加和有利的政策改革。

全球α粒子發射材料市場的成長要素

醫療機構對高解析度成像的需求日益成長，顯著推動了α放射性藥物的應用，這類藥物以其卓越的對比度和組織特異性而聞名。醫療機構正在尋求能夠實現疾病早期檢測和精準分期的藥物，這促使生產商拓展產品線。這些臨床需求刺激了研發投入的大幅成長，並加快了法規核准流程，並促進了醫療產業內部的合作，從而推動了市場的強勁成長。隨著治療方案的不斷改進和標靶放射療法的日益普及，對精準α放射性藥物的依賴性也在不斷增強，從而擴大了成熟市場和新興市場的需求。

全球α粒子發射市場的限制因素

由於α粒子發射體具有高輻射中毒，因此受到嚴格的安全和環境法規的限制，全球α粒子發射設備市場面臨許多挑戰。製造商必須經過全面的核准流程，包括提交大量文件、進行詳細的風險評估、制定長期監測策略以及執行嚴格的操作規程。這些監管挑戰不僅延長了研發週期，還推高了營運成本，並可能阻礙新進業者。這種情況可能會限制產品的供應，阻礙醫療專業人員採用α粒子發射設備，從而在臨床需求持續存在的情況下影響市場成長。不斷更新的監管規定要求企業持續進行合規工作，這可能會進一步分散市場創新和發展動力。

全球α粒子發射材料市場趨勢

全球α放射性藥物市場正呈現出顯著的成長趨勢，尤其是在標靶放射性藥物領域，其應用範圍正在不斷擴大。臨床醫生擴大採用α放射性藥物，因為它們能夠利用致命輻射直接靶向癌細胞，同時最大限度地減少對周圍健康組織的損傷。同位素生產技術的創新、先進的遞送分子以及與影像診斷技術的更緊密結合，使得劑量傳遞更加精準，治療應用範圍也從傳統的前列腺癌和神經內分泌腫瘤擴展到淋巴瘤和轉移性乳癌等疾病。這種不斷成長的臨床應用勢頭正在推動醫院採購，促進與生物技術公司的策略合作，並鞏固α放射性藥物在未來腫瘤治療中的關鍵地位。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球α放射性物質市場規模：依放射性核類型分類

• 鐳-223
• 錒-225
• 砈-211
• 鉛-212
• 鉍-212
• 其他

全球α粒子發射設備市場規模：依腫瘤內科領域分類

• 進行性前列腺癌
• 骨轉移
• 難治性卵巢癌
• 胰臟癌
• 內分泌腫瘤和神經內分泌腫瘤
• 其他

全球α粒子發射材料市場規模：依生產方法與技術分類

• 核能研究核子反應爐
• 粒子迴旋加速器與加速器
• 發生器所產生的放射性核種

全球α粒子發射設備市場規模：依醫療領域終端用戶分類

• 癌症專科醫院
• 核子醫學和診斷中心
• 學術研究醫療機構

全球α粒子發射材料市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Bayer AG
• Novartis AG
• Eckert & Ziegler AG
• Curium SA
• Actinium Pharmaceuticals Inc.
• Telix Pharmaceuticals Limited
• Fusion Pharmaceuticals Inc.
• Lantheus Holdings Inc.
• Point Biopharma Global Inc.
• RadioMedix Inc.
• NorthStar Medical Radioisotopes LLC
• Shine Technologies LLC
• Niowave Inc.
• TerraPower LLC
• Orano SA
• Eisai Co. Ltd.
• Y-mAbs Therapeutics Inc.
• RayzeBio Inc.
• Mariana Oncology
• ARTBIO Inc.

結論與建議

Global Alpha Emitter Market size was valued at USD 1.25 Billion in 2024 and is poised to grow from USD 1.45 Billion in 2025 to USD 4.68 Billion by 2033, growing at a CAGR of 15.8% during the forecast period (2026-2033).

The global alpha emitter market is experiencing significant growth driven by the rising demand for precision oncology, as healthcare professionals seek therapies that minimize collateral damage compared to traditional radiation treatments. The introduction of innovative products such as 225Ac-PSMA-617 has motivated pharmaceutical companies to invest heavily in isotope production and labeling technologies. Hospitals are experimenting with combining alpha emitters and immunotherapy to enhance tumor-specific immune reactions. Additionally, aerospace sectors are investigating alternative isotopes like plutonium-238, diversifying market applications. AI-enabled automation is reshaping the value chain, enhancing isotope discovery, production quality, and clinical workflows, which boosts efficiency, affordability, and safety in treatment delivery. This convergence of diverse applications and technology advancements is propelling the alpha emitter market forward, garnering increased venture capital and favorable policy reforms.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Alpha Emitter market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Alpha Emitter Market Segments Analysis

Global alpha emitter market is segmented by type of radionuclide, medical oncological application, production methodology technology, healthcare end user and region. Based on type of radionuclide, the market is segmented into Radium-223, Actinium-225, Astatine-211, Lead-212, Bismuth-212 and Others. Based on medical oncological application, the market is segmented into Advanced Prostate Cancer, Skeletal Bone Metastasis, Refractory Ovarian Cancer, Pancreatic Cancer, Endocrine and Neuroendocrine Tumors and Others. Based on production methodology technology, the market is segmented into Nuclear Research Reactors, Particle Cyclotrons and Accelerators and Generator Sourced Radionuclides. Based on healthcare end user, the market is segmented into Oncology Specialized Hospitals, Nuclear Medicine and Diagnostic Centers and Academic Research Medical Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Alpha Emitter Market

The growing demand for high-resolution imaging in medical facilities is significantly boosting the adoption of alpha emitters, recognized for their exceptional contrast and tissue specificity. Healthcare providers are on the lookout for agents that facilitate early disease detection and precise staging, prompting manufacturers to expand their product offerings. This clinical need stimulates substantial investment in research and development, expedites regulatory approvals, and encourages collaborations within the healthcare sector, thereby fostering robust market growth. As treatment protocols evolve to increasingly include targeted radiotherapy, the dependence on accurate alpha-emitting agents rises, enhancing demand across both mature and emerging markets.

Restraints in the Global Alpha Emitter Market

The Global Alpha Emitter market faces significant constraints due to stringent safety and environmental regulations stemming from the high radiotoxicity associated with these emitters. Manufacturers are required to undergo comprehensive approval processes that involve extensive documentation, detailed risk assessments, long-term monitoring strategies, and rigorous handling protocols. These regulatory challenges not only extend development timelines but also escalate operational costs, potentially discouraging new market entrants. This landscape can restrict product availability and impede the adoption of alpha emitters by healthcare providers, thereby affecting market growth in the face of consistent clinical demand. Ongoing legislative updates necessitate relentless compliance efforts, which can further divert focus away from innovation and momentum in the market.

Market Trends of the Global Alpha Emitter Market

The Global Alpha Emitter market is witnessing a notable trend towards the expansion of medical therapies, particularly in the realm of targeted radiopharmaceuticals. Clinicians are increasingly adopting alpha emitters for their ability to deliver targeted, lethal radiation directly to cancerous cells while minimizing damage to surrounding healthy tissue. Innovations in isotope production, advanced carrier molecules, and enhanced imaging integration are facilitating more accurate dose delivery and broadening the therapeutic applications to include conditions such as lymphoma and metastatic breast cancer, beyond the established focus on prostate and neuroendocrine tumors. This growing clinical momentum is fueling procurement by hospitals, encouraging strategic partnerships with biotech companies, and solidifying alpha emitters' role as a pivotal component in the future of oncology treatment.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Alpha Emitter Market Size by Type of Radionuclide & CAGR (2026-2033)

• Market Overview
• Radium-223
• Actinium-225
• Astatine-211
• Lead-212
• Bismuth-212
• Others

Global Alpha Emitter Market Size by Medical Oncological Application & CAGR (2026-2033)

• Market Overview
• Advanced Prostate Cancer
• Skeletal Bone Metastasis
• Refractory Ovarian Cancer
• Pancreatic Cancer
• Endocrine and Neuroendocrine Tumors
• Others

Global Alpha Emitter Market Size by Production Methodology Technology & CAGR (2026-2033)

• Market Overview
• Nuclear Research Reactors
• Particle Cyclotrons and Accelerators
• Generator Sourced Radionuclides

Global Alpha Emitter Market Size by Healthcare End User & CAGR (2026-2033)

• Market Overview
• Oncology Specialized Hospitals
• Nuclear Medicine and Diagnostic Centers
• Academic Research Medical Institutes

Global Alpha Emitter Market Size & CAGR (2026-2033)

• North America (Type of Radionuclide, Medical Oncological Application, Production Methodology Technology, Healthcare End User)
  • US
  • Canada
• Europe (Type of Radionuclide, Medical Oncological Application, Production Methodology Technology, Healthcare End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type of Radionuclide, Medical Oncological Application, Production Methodology Technology, Healthcare End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type of Radionuclide, Medical Oncological Application, Production Methodology Technology, Healthcare End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type of Radionuclide, Medical Oncological Application, Production Methodology Technology, Healthcare End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eckert & Ziegler AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curium SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Actinium Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Telix Pharmaceuticals Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fusion Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lantheus Holdings Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Point Biopharma Global Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RadioMedix Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NorthStar Medical Radioisotopes LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shine Technologies LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Niowave Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TerraPower LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orano SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Y-mAbs Therapeutics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RayzeBio Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mariana Oncology
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ARTBIO Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations